Recently, the clinical trial of combination of elemene and EGFR-TKI for advanced EGFR-TKI-resistant NSCLC has been approved in China (ChiCTR-IPR-17012912 and NCT03123484), promoting further evaluation and mechanistic understanding of elemene to be as an adjuvant for the combinative therapy. Here, EGFR is linked to non-small cell lung carcinoma.